Aspiriant Capital Appreciation Fund updated its prospectus for a continuous $250 million public offering, with net annual expenses of 4.83% after waivers. Investors generally subscribe quarterly and rely on approximately 5% quarterly repurchase offers for liquidity.

Aspiriant Capital Appreciation Fund offered to repurchase up to 5.00% of net assets, $7.2 million or 643,501 shares, at September 30, 2026 net asset value. Investors must tender by September 16, 2026; if accepted, they receive at least 98% within 65 days.

Aspiriant Capital Appreciation Fund provided its 2026 annual proxy voting notice for the year ended June 30, 2026, with no series or explanatory information included.

Aspiriant Capital Appreciation Fund reported final tender offer results: four shareholders had tendered shares accepted with $2.5 million net asset value as of March 31, 2026, and received 100% unaudited value on May 15, 2026.

Aspiriant Capital Appreciation Fund is offering to repurchase up to approximately 5.00% of net assets, or about $7.5 million and 653,537 Shares, at NAV, with tenders due by June 17, 2026 and valuation as of June 30, 2026. Accepted tendering Shareholders will receive a non-interest-bearing promissory note with at least 98% paid in cash within about 65 days and any balance after the next annual audit.

Variant Alternative Income Fund renewed joint fidelity bond coverage from December 31, 2025 to December 31, 2026, with $2.5 million limits and a $250,000 electronic mail fraud sub-limit. Participating funds share premiums and any inadequate recovery under the joint agreement.

Aspiriant Capital Appreciation Fund’s final amendment reports that its $7.0 million tender offer was accepted from five Shareholders, with tendered Shares having $1.26 million of NAV as of December 31, 2025. Four Shareholders received full cash payments, and one Shareholder received at least 98% now with a contingent post-audit payment due after the May 2026 audit.

Aspiriant Capital Appreciation Fund filed a final amendment reporting the results of its $6.9 million tender offer: five Shareholders tendered and the Fund accepted Shares with an aggregate NAV of $1.6 million. Cash payments were wired on November 18, 2025, and any Post-Audit Payment will be made after the annual audit expected by the end of May 2026.

Aspiriant Capital Appreciation Fund is offering to repurchase up to 5.00% of net assets, or about $7.3 million and 616,344 Shares, at NAV, with tenders due by March 16, 2026 and valuation on March 31, 2026. Accepted Shareholders will receive a non-interest-bearing promissory note, with at least 98% paid in cash within about 65 days and any balance after the annual audit.

Aspiriant Capital Appreciation Fund will repurchase up to approximately 5% of net assets, or about $6.9 million and 616,634 Shares, at NAV, with tenders due by December 17, 2025 and pricing as of December 31, 2025. Accepted Shareholders will receive a non-interest-bearing Note, with at least 98% paid in cash about 65 days after the deadline and any balance after audit.